Print
Email
Print Edition Stories
BP hones skills through MIT programs
Homeland Security Sec. Napolitano speaks with universities
MHT's Julie Donnelly: Pharmaceuticals find drug development partners in colleges
Rockland-based EMD Serono Inc., an affiliate of Merck KGaA, has restarted its Stimuvax clinical program for patients with non-small cell lung cancer. The program includes the Phase 3 studies of EMD Serono’s BLP25 liposome vaccine, a therapeutic cancer vaccine that the company has applied for Investigational New Drug status.
The reinstatement of the program follows an announcement in March that the U.S. Food and Drug Administration put a clinical hold on the program after a multiple myeloma patient in an experimental Phase 2 trial developed encephalitis.
As a result, the reinstatement of the clinical program for non-small cell lung cancer entails additional safety measures. BLP25 remains on clinical hold with the company’s trial in advanced breast cancer.
EMD Serono focuses its treatments on neurodegenerative diseases and diseases associated with endorcrinology and reproduction.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
